Salah Abohelaika1, Hilary Wynne2, Peter Avery3, Brian Robinson4, Patrick Kesteven4, Farhad Kamali5. 1. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. 2. Older People's Medicine, Newcastle upon Tyne Hospitals, NHS Foundation Trust, UK. 3. School of Mathematics and Statistics, Newcastle University, Newcastle upon Tyne, UK. 4. Department of Haematology, Newcastle upon Tyne Hospitals, NHS Foundation Trust, UK. 5. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. farhad.kamali@ncl.ac.uk.
Abstract
AIMS: Stabilization of anticoagulation control is seminal to reducing the risk of adverse effects of vitamin K antagonists. Reliable information on how ageing influences this is lacking. We set out to assess the true age-related changes in anticoagulation control, how gender and patient setting influence this, and the possible implications of these for patient outcomes and management. METHODS: In atrial fibrillation (AF) patients of a unified anticoagulant service monitoring patients in general practice or hospital-based clinics and housebound patients at home, international normalized ratio (INR) and warfarin dose data between 2000 and 2013 were extracted via the DAWN dosing program. Anticoagulation control was assessed by calculating percentage time spent within target INR (TTR). RESULTS: A total of 2094 AF patients [938 (44.8%) in general practice (GP) and 531 (25.4%) in hospital (H)-based clinics and 625 (29.8%) through the domiciliary service (D)] were evaluated. The frequency of warfarin dose changes and INR monitoring events declined until about age 67, then increased as patients got older. The TTR according to age was significantly lower and the probability of having a TTR ≤65% according to age was higher for D than for H and GP, and females had a greater probability of having a TTR ≤65% than age-matched males. CONCLUSION: Identification of factors underlying poorer anticoagulation control in older housebound patients and the introduction of effective modifications to improve the clinical effectiveness of anticoagulation in such patients is needed.
AIMS: Stabilization of anticoagulation control is seminal to reducing the risk of adverse effects of vitamin K antagonists. Reliable information on how ageing influences this is lacking. We set out to assess the true age-related changes in anticoagulation control, how gender and patient setting influence this, and the possible implications of these for patient outcomes and management. METHODS: In atrial fibrillation (AF) patients of a unified anticoagulant service monitoring patients in general practice or hospital-based clinics and housebound patients at home, international normalized ratio (INR) and warfarin dose data between 2000 and 2013 were extracted via the DAWN dosing program. Anticoagulation control was assessed by calculating percentage time spent within target INR (TTR). RESULTS: A total of 2094 AFpatients [938 (44.8%) in general practice (GP) and 531 (25.4%) in hospital (H)-based clinics and 625 (29.8%) through the domiciliary service (D)] were evaluated. The frequency of warfarin dose changes and INR monitoring events declined until about age 67, then increased as patients got older. The TTR according to age was significantly lower and the probability of having a TTR ≤65% according to age was higher for D than for H and GP, and females had a greater probability of having a TTR ≤65% than age-matched males. CONCLUSION: Identification of factors underlying poorer anticoagulation control in older housebound patients and the introduction of effective modifications to improve the clinical effectiveness of anticoagulation in such patients is needed.
Authors: Barclay M Goudie; Peter T Donnan; Geraldine Fairfield; Sally S Al-Agilly; Philip G Cachia Journal: Br J Gen Pract Date: 2004-09 Impact factor: 5.386
Authors: Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly Journal: Lancet Date: 2010-09-18 Impact factor: 79.321
Authors: Salah Abohelaika; Farhad Kamali; Peter Avery; Brian Robinson; Patrick Kesteven; Hilary Wynne Journal: Age Ageing Date: 2014-06-18 Impact factor: 10.668
Authors: Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray Journal: Lancet Date: 2007-08-11 Impact factor: 79.321
Authors: Campbell Cowan; Richard Healicon; Ian Robson; W Robert Long; James Barrett; Matthew Fay; Keith Tyndall; Chris P Gale Journal: Heart Date: 2013-02-07 Impact factor: 5.994
Authors: Aníbal García-Sempere; Isabel Hurtado; Daniel Bejarano-Quisoboni; Clara Rodríguez-Bernal; Yared Santa-Ana; Salvador Peiró; Gabriel Sanfélix-Gimeno Journal: PLoS One Date: 2019-02-12 Impact factor: 3.240
Authors: José Felipe Varona; José Miguel Seguí-Ripoll; Cristina Lozano-Duran; Luis Miguel Cuadrado-Gómez; Juan Bautista Montagud-Moncho; Antonio Ramos-Guerrero; José Carlos Mirete-Ferrer; Esther Donado; Javier García-Alegría Journal: Health Qual Life Outcomes Date: 2020-12-11 Impact factor: 3.186